SNY Stock Analysis: Buy, Sell, or Hold?
SNY - Sanofi American Depositary Shares (Each representing one-half of one ordinary share)
$43.18
-0.82 (-1.86%)
▼
5d:
+0.47%
30d:
-2.11%
90d:
-8.05%
BUY
HIGH Confidence
Analysis Updated: Jul 14, 2026 12:00 AM ET
Earnings: Jul 30, 2026
14d
Get Alerted When SNY Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
✅ BUY SIGNAL: SNY shows strong fundamentals and good volume confirmation. Solid entry point despite fair pricing.
✅ BUY SIGNAL: SNY shows strong fundamentals and good volume confirmation. Solid entry point despite fair pricing.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$58.86
Based on 5.6% avg growth
INTRINSIC VALUE TODAY
$36.55
Trading above historical range
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 8.7x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: SNY is currently trading at $43.18, which is considered fair relative to its 30-day fair value range of $42.16 to $44.12. The stock's valuation (Forward PE: 8.4) is in line with its historical norms (8.7). Remarkably, the market is currently pricing in an annual earnings decline of 1.2% over the next few years. This aligns with recent fundamental challenges.
Technical Outlook: Technically, SNY is in a strong downtrend. The price is approaching resistance at $44.13. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: SNY has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $55.06 (+27.5%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, SNY is in a strong downtrend. The price is approaching resistance at $44.13. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: SNY has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $55.06 (+27.5%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
FAIR
Historical Trading Range
$42.16 -
$44.12
Company Quality Score
62/100
(BUY)
Volume Confirmation
HIGH
Confidence Score
83.3%
All Signals
- NEUTRAL: Price in fair range
- BULLISH: Strong technical setup (60/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 27.5% below Wall St target ($55.06)
Trading Range Analysis
30-Day Trading Range
$42.16 -
$44.12
Current vs Trading Range
FAIR
Support & Resistance Levels
Support Level
$41.27
Resistance Level
$44.13
Current Trend
Strong Downtrend
Technical data as of
Jul 14, 2026
Fundamental Context
Forward P/E (Next Year Est.)
8.40
Wall Street Target
$55.06
(+27.5%)
Revenue Growth (YoY)
6.0%
Earnings Growth (YoY)
-11.7%
Profit Margin
16.0%
Valuation Discount vs History
-1.2% cheaper
PE vs Historical
8.4 vs 8.7
FAIR
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
-1.2%
(market-implied from PE analysis)
1-Year Target
$42.66
(-1%)
2-Year Target
$42.15
(-2%)
3-Year Target
$41.64
(-4%)
3-Yr Target (if PE normalizes)
(PE: 8→9)
$43.14
(0%)
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 21.8, Growth: 7.3%)
$138.47
(+221%)
Base:
(SPY PE: 8.4, Growth: 7.3%)
$53.39
(+24%)
Bear:
(PE: 7.1, Growth: 7.3%)
$45.38
(+5%)
📈
Valuation based on Current Earnings
RECOVERY PLAY: Stock looks expensive now (19x PE), but valuation improves significantly next year (8x PE) as earnings recover.
Trailing PE: 19.33 | Current EPS (TTM): $2.25
Bull Case
$95.70
(+122%)
Analyst growth 100.0%, PE expands to 21.3
Base Case
$87.00
(+102%)
Market implied 100.0%, PE stable at 19.3
Bear Case
$29.58
(-32%)
Severe decline -20.0%, PE contracts to 16.4
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
💡
Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 8.4 to 8.7
Stabilization Target:
$44.73
(+3.6%)
PE Expansion Potential:
+3.6%
Share & Embed Analysis
Last updated: July 15, 2026 1:58 AM ET
Data refreshes hourly during market hours. Next update: 2:58 AM
Data refreshes hourly during market hours. Next update: 2:58 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is SNY showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Drug Manufacturers - General Stocks
Top-rated stocks in Drug Manufacturers - General by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
LLY
Eli Lilly and Company |
STRONG BUY
31 analysts |
$1240 | 56 HOLD |
|
GILD
Gilead Sciences Inc |
BUY
30 analysts |
$158 | 65 BUY |
|
ABBV
AbbVie Inc |
BUY
28 analysts |
$263 | 58 HOLD |
|
BIIB
Biogen Inc |
HOLD
37 analysts |
$223 | 59 HOLD |
|
AMGN
Amgen Inc |
HOLD
32 analysts |
$356 | 56 HOLD |
